Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | HTR1F | P30939 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101106 | 1.00 | KDM4E (0.57) | KDM4ELMNAALOX15NPC1HTT | |
| SCHEMBL30909151 | 0.77 | HTR1F (0.53) | KDM4ELMNAALOX15HTR1FSLC6A4 | |
| SCHEMBL7095944 | 0.77 | HTR1F (0.53) | KDM4ELMNAALOX15HTR1FSLC6A4 | |
| SCHEMBL8457517 | 0.73 | HTR1F (0.56) | KDM4ELMNAALOX15NPC1HTT | |
| Hydrochloric Acid SCHEMBL11316658 | 0.73 | KDM4E (1.00) | KDM4ELMNAALOX15NPC1HTT | |
| SCHEMBL11320474 | 0.73 | KDM4E (1.00) | KDM4ELMNAALOX15NPC1HTT | |
| SCHEMBL7012793 | 0.71 | HTR1F (0.76) | KDM4ELMNAALOX15HTR1FSLC6A4 | |
| SCHEMBL7011728 | 0.70 | HTR1F (0.71) | KDM4ELMNAALOX15HTTHTR1F | |
| SCHEMBL7010488 | 0.70 | SLC6A4 (0.47) | KDM4ELMNAALOX15HTR1FSLC6A4 | |
| SCHEMBL7008686 | 0.69 | HTR1F (1.00) | KDM4ELMNAALOX15HTR1FHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | KDM4E 3551/4885LMNA 4061/4885ALOX15 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.